Krystal Biotech, Inc. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Krystal Biotech, Inc. (KRYS) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of $5.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-02-17
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was $5.23M, a 57.63% increase from fiscal 2024.
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was $3.32M.
- Krystal Biotech, Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | $5.23M 10-K · filed 2026-02-17 |
| 2024-12-31 | $3.32M 10-K · filed 2026-02-17 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |